We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+122.93%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$236M
AUM Growth
–
Cap. Flow
+$179M
Cap. Flow %
75.86%
Top 10 Hldgs %
65.68%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 quarters
Top 10 Avg Time Held Equity + Options
0 quarters
Top 20 Avg Time Held Equity + Options
0 quarters
Avg Time Held Equity only
0 quarters
Top 10 Avg Time Held Equity only
0 quarters
Top 20 Avg Time Held Equity only
0 quarters

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$22.4M
2
COGT icon
Cogent Biosciences
COGT
+$21.9M
3
MAZE
Maze Therapeutics
MAZE
+$16.8M
4
ABVX
Abivax
ABVX
+$15.8M
5
KALV
KalVista Pharmaceuticals
KALV
+$9.27M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94.97%
2 Miscellaneous 5.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KTTA icon
26
Pasithea Therapeutics
KTTA
$15.3M
$2.71M 1.15%
+2,100,000
New +$1.85M
2025 Q4
0 quarters
CMPS
27
Compass Pathways
CMPS
$1.65B
$2.68M 1.14%
+388,287
New +$2.37M
2025 Q4
0 quarters
AVTX icon
28
Avalo Therapeutics
AVTX
$734M
$2.36M 1%
+130,000
New +$2.19M
2025 Q4
0 quarters
IVA
29
Inventiva
IVA
$749M
$1.4M 0.59%
+300,000
New +$1.39M
2025 Q4
0 quarters
ZBIO
30
CALL
Zenas BioPharma
ZBIO
$1.77B
$1.31M 0.55%
+36,000
New +$1.18M
2025 Q4
0 quarters
TRAW icon
31
Traws Pharma
TRAW
$6.8M
$806K 0.34%
+713,540
New +$1.59M
2025 Q4
0 quarters
NTLA icon
32
CALL
Intellia Therapeutics
NTLA
$1.82B
$728K 0.31%
+81,000
New +$1.12M
2025 Q4
0 quarters
CLYM
33
Climb Bio
CLYM
$638M
$400K 0.17%
+100,000
New +$240K
2025 Q4
0 quarters
1
2

Similar funds

SST
S Squared Technology New York $322M AUM 92.75% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $322M AUM 16.26% 1-Year Est. Return
WW
Westshore Wealth Newport Beach, California $322M AUM 24.46% 1-Year Est. Return
NAG
Northstar Advisory Group Northfield, New Jersey $322M AUM 36.79% 1-Year Est. Return
JGIA
Jackson Grant Investment Advisers Stamford, Connecticut $322M AUM 20.03% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $322M AUM
KF
Ketron Financial Novato, California $322M AUM
QFPS
Quantum Financial Planning Services Spokane, Washington $323M AUM 14.02% 1-Year Est. Return

Squadron Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Squadron Capital Management, which disclosed 33 positions worth $236M. Its ten largest holdings account for 66% of the portfolio.

Its largest position is Relmada Therapeutics: 6,700,000 shares worth $32.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous.

  • Squadron Capital Management's largest Q4 2025 buy was Relmada Therapeutics: 6,700,000 shares worth $32.4M.
  • Squadron Capital Management's ten largest holdings make up 66% of its $236M portfolio in Q4 2025.
  • Squadron Capital Management disclosed 33 positions in Q4 2025, its first 13F filing on record.

Based on Squadron Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.